graph VTE
  • In the AMPLIFY trial, patients ≥100 kg (220 lb) receiving apixaban experienced similar rates of recurrent VTE or VTE-related death, or major bleeding as others in the trial
AMPLIFY Weight and BMI Subgroup Analysis
  • AMPLIFY post hoc analysis: Acknowledging the limited numbers of patients in the ≥120 kg body weight category, the safety and efficacy of apixaban in patients with extremes of body weight were consistent with the main results of the AMPLIFY trial
AMPLIFY Post hoc Analysis Extremes of Body Weight & Exposure
  • AMPLIFY post hoc pharmacokinetic analysis: There was a small, non-clinically significant decrease (<30%) in the median predicted exposure to apixaban with increasing body weight categories
AMPLIFY-EXT Weight Subgroup Analysis
  • In a retrospective analysis of pooled data in patients with obesity/ morbid obesity from the fee-for-service CMS Medicare database and 4 US commercial claims databases, regardless of the obesity status, effects of apixaban versus warfarin on recurrent VTE and MB were consistent and showed lower rates for apixaban compared to warfarin
Cohen A (J Clin Med 2021)
Effectiveness and safety of apixaban vs. warfarin in venous thromboembolism patients with obesity and morbid obesity